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Abstract
A precise molecular identification of transmitted hepatitis C virus (HCV) genomes could illuminate key aspects of
transmission biology, immunopathogenesis and natural history. We used single genome sequencing of 2,922 half or quarter
genomes from plasma viral RNA to identify transmitted/founder (T/F) viruses in 17 subjects with acute community-acquired
HCV infection. Sequences from 13 of 17 acute subjects, but none of 14 chronic controls, exhibited one or more discrete low
diversity viral lineages. Sequences within each lineage generally revealed a star-like phylogeny of mutations that coalesced
to unambiguous T/F viral genomes. Numbers of transmitted viruses leading to productive clinical infection were estimated
to range from 1 to 37 or more (median = 4). Four acutely infected subjects showed a distinctly different pattern of virus
diversity that deviated from a star-like phylogeny. In these cases, empirical analysis and mathematical modeling suggested
high multiplicity virus transmission from individuals who themselves were acutely infected or had experienced a virus
population bottleneck due to antiviral drug therapy. These results provide new quantitative and qualitative insights into
HCV transmission, revealing for the first time virus-host interactions that successful vaccines or treatment interventions will
need to overcome. Our findings further suggest a novel experimental strategy for identifying full-length T/F genomes for
proteome-wide analyses of HCV biology and adaptation to antiviral drug or immune pressures.
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Introduction
Hepatitis C virus (HCV) infects as many as 170 million people
or nearly 3% of the world’s population. The virus causes a wide
variety of pathologic outcomes, the most significant being chronic
liver disease, cirrhosis and hepatocellular carcinoma, which is
nearly always fatal. HCV infection is the leading indication for
liver transplantation in the United States [1].
HCV is a positive strand, non-segmented, enveloped RNA virus
of approximately 9.6 kb in length. The virus is classified in the
genus Hepacivirus within the larger family of Flavivirus, which
includes the human pathogens West Nile virus, yellow fever virus
and dengue fever virus among others [2]. A common feature
among the Flaviviridae is their dependence on a virally-encoded
RNA-dependent RNA polymerase (RdRp) for replication [3].
RdRp is error-prone, and HCV is notable for its extensive
diversity within and among individuals. Globally, there are seven
major genotypes of HCV that differ by approximately 30% in
nucleotide sequence [1,4,5].
The extraordinary diversity of HCV complicates studies of virus
biology, pathogenesis and susceptibility to novel therapeutics.
Clinically, the different HCV genotypes exhibit variable natural
history and responsiveness to interferon, ribavirin and the newer
direct acting antiviral (DAA) agents [2,6,7]. HCV variation poses
similar challenges to the development of effective vaccines and to
the elucidation of viral immunopathogenesis [5,8–10]. It is of
interest then that the extraordinary diversity of HCV is similar to
that of HIV-1 and that a novel experimental strategy to identify
transmitted/founder (T/F) HIV-1 genomes has led to new insights
into virus transmission and persistence [11–18].
Acute HCV infection isconventionally defined as the initial 6
months of infection and sets into motion virus-host interactions
that to a large extent dictate the natural history of the disease
[9,10,19–30]. Depending on viral genotype and host immunoge-
netic factors, most importantly IL28B alleles, a proportion of
newly infected individuals spontaneously controls or eliminates
virus [9,10,31–33]. A greater number can be cured if the infection
is treated with interferon and ribavirin alone or in combination
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with DAA drugs [6,34–36]. Mechanistically, how this occurs is
incompletely understood. From a vaccine perspective, the acute
infection period is critical, since transmitted viruses are the obvious
targets of a vaccine and early stages of infection when viral
diversity is lowest represent a period when the virus may be most
vulnerable to elimination by vaccine-elicited immune responses
[26,37]. For all these reasons, there is considerable interest in the
molecular features of the initial virus population ‘bottleneck’
associated with virus transmission and the subsequent pathways of
virus evolution that lead to persistence [19–25,28,29,38,39].
Previous reports have described different experimental ap-
proaches to the analysis of the HCV transmission bottleneck.
These include studies that employed a DNA heteroduplex gel shift
method to estimate viral diversity [39,40], conventional polymer-
ase chain reaction (PCR) methods to bulk amplify, sequence, or
clone and sequence fragments of HCV genomes
[20,21,23,25,28,38,41,42], and 454 pyrosequencing to interrogate
early viral sequences more deeply but narrowly [19,43]. These
reports documented a restriction in viral diversity associated with
virus transmission, but despite the use of increasingly sensitive
methods, a precise quantitative, molecular description of HCV
transmission and early diversification has remained elusive. In the
current study, we hypothesized that T/F HCV genomes could be
identified unambiguously and their early pathways of diversifica-
tion mapped precisely by single genome amplification (SGA)
followed by direct amplicon sequencing, otherwise known as single
genome sequencing [17], an approach we used previously to gain
insight into HIV-1 transmission [15,18]. This strategy differs from
previous methods applied to HCV by providing gene-wide or
genome-wide viral sequences that are proportional to their
representation in human plasma and are not confounded by
template resampling or by Taqpolymerase errors of nucleotide
misincorporation or recombination [15,17,18,44–47]. We ampli-
fied and sequenced HCV core, E1, E2, P7, NS2 and NS3 genes
and analyzed them by adapting a model of random HIV-1
evolution [15,48,49] to account for differences in the biology of
replication between the HIV-1 and HCV. In an accompanying
report, Ribeiro and colleagues [50] used these sequences together
with plasma viral load kinetic data to develop an agent based
stochastic model of acute HCV replication dynamics resulting in
new estimates of the HCV mutation rate in humans.
Results
Study subjects, viral load measurements and single
genome sequencing
One hundred fifty-four plasma specimens from 17 subjects with
acute HCV infection and 14 subjects with chronic HCV infection
were analyzed for viral RNA (vRNA) load (Figure 1; Table S1).
Acute infection subjects were source plasma donors who had
undergone once or twice weekly plasmapheresis for months, and
in some cases years, with persistently negative testing for HCV,
HBV and HIV antibody or RNA before becoming acutely
infected by HCV. Chronically infected subjects were patients at
the University of Alabama at Birmingham who were known to
have been HCV infected for approximately 3 to .20 years. All
subjects were untreated with anti-HCV medications. A median of
8 (range 5–11) sequential specimens per acutely infected subject
was analyzed for vRNA load spanning the period of plasma vRNA
negativity through exponential increase to an early plateau
(Figure 1), and a subset of these was analyzed for sequence
diversity. The median peak plasma viral load in acute infection
subjects was 2,850,000 IU/ml (range = 527,000–10,300,000 IU/
ml). Five of 17 acutely infected subjects developed HCV antibodies
by the last sampling time point. Chronic subjects had a median
vRNA load of 2,081,138 IU/ml (range = 24,000–7,690,001 IU/
ml), all were HCV antibody positive, and all were sampled once
for vRNA sequence diversity. A total of 2003 59 half genomes and
919 59 quarter genomes were amplified, sequenced, and recorded
(Genbank accession numbers JQ801756–JQ804520; JX178293–
178443).
Phylogenetic analysis of acute and chronic sequences
Sequences corresponding to core antigen and envelope E1 and
E2 genes (2.2 kb) from the initial HCV RNA positive sample from
acute and chronic subjects were subjected to maximum-likelihood
(ML) phylogenetic analysis (Figure 2). Sequences formed subject-
specific clades (bootstraps 93–100%) and represented HCV
genotypes 1a (n = 23), 1b (n = 4), 2b (n = 2) or 3a (n = 2). No
subject was infected by more than one virus genotype and there
was no intermixing of sequences between subjects in the
phylogenetic tree. Sequences from acute and chronic subjects
revealedwidely varying degrees of maximum within-subject
diversity ranging from 0.14% to 6.40% (Tables 1 and S1), which
was not different between the two groups (p.0.05, Mann-Whitney
test). Acute sequences were, however, distinctly different from
chronic sequences in having one or more discrete lineages
characterized by extremely low diversity. This was true for
sequences from each acutely infected subject but from none of the
chronically infected subjects. Maximum diversity of sequences
within these discrete viral lineages from acute subjects (mean
0.12%; median 0.12%; range 0.04–0.19%) was significantly lower
than the overall diversity observed within chronic subjects (mean
2.27%; median 2.37%; range 0.56–3.83%; p,0.0001, unpaired
T-test with Welch’s correction) (Figure S1).
Mathematical models of early HCV diversification
Because of the distinctive replication strategy of HCV, which is
still not fully understood [3,5], we could not predict a priori the
patterns of early virus diversification that we might observe in
acutely infected subjects. Thus, we developed two mathematical
Author Summary
Hepatitis C virus infects as many as 170 million people
worldwide. Globally, there are seven major genotypes of
HCV that differ by approximately 30% in nucleotide
sequence. Importantly, the natural history of HCV infection
is variable, ranging from spontaneous resolution to
persistent viremia and chronic disease. Factors responsible
for this variability in clinical outcome are unknown but
likely involve a combination of viral and host determinants.
To this end, a precise molecular identification of transmit-
ted HCV genomes could illuminate key aspects of
transmission biology, immunopathogenesis and natural
history. We used single genome sequencing of plasma
viral RNA to identify transmitted viral genomes and their
progeny in 17 subjects with acute infection. Numbers of
transmitted viruses leading to productive clinical infection
ranged from 1 to 37 or more (median = 4). Surprisingly, we
found evidence of high multiplicity acute-to-acute HCV
transmission in 3 of 17 subjects, which suggests that
clinical transmission of HCV, like that of HIV-1, may be
enhanced in early infection when virus titers are highest
and neutralizing antibodies are absent. These results
provide novel insight into HCV transmission and early
virus diversification key to our understanding of virus
natural history and response to drug selection and
immune pressure.
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models to analyze HCV sequence diversity (Figure 3). The first
model [15,48,49], employed previously to analyze early HIV-1
sequence diversification, assumes a narrow genetic bottleneck
associated with virus transmission, initial rapid exponential virus
growth, constant lineage-independent mutation rates at all sites, no
recombination between sequences or back mutations, and no
differential selection. When diversity is low, most base substitutions
occur at distinct loci, pairwise differences between sequences (i.e.,
Hamming distances, HD) follow a Poisson distribution, and
sequences exhibit a star-like phylogeny and coalesce to distinct
unambiguous T/F genomes [15,18,51]. Early HIV-1 diversifica-
tion conforms well to this model and it was suggested that other
viruses including HCV might also [48]. However, HCV replica-
tion differs from HIV-1 in that HCV RNA does not integrate into
chromosomal DNA and it does not produce all of its daughter
progeny in a large burst of viruses within a couple days after
infecting a cell [52]. Instead, it forms as many as 40 cytosolic
replication complexes that continue to produce virions throughout
the lifetime of the cell [50,53]. In early infection prior to the onset
of HCV specific cellular immune responses, the lifetime of
infectedcells is likely to span our sampling period given that the
lifetime of uninfected hepatocytes is estimated to be months to
years [54,55]. To account for these differences with HIV-1, we
developed an alternative simplified deterministic model of HCV
diversification (Figure 3). This model predicts occasional violations
in star-like diversification and in the Poisson fit of mutations with
Figure 1. HCV plasma viral RNA kinetics in acute infection subjects. PlasmavRNA was quantified by Roche COBAS AmpliPrep/Taqman HCV
assay. Circled values indicate samples subjected to vRNA sequencing and plus signs denote HCV antibody positivity.
doi:10.1371/journal.ppat.1002880.g001
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increasing probability as time goes on, and it predicts greater
numbers of shared stochastic mutations between HCV sequences
compared with HIV-1 sequences. The latter model provided us
with a mathematical and statistical basis for distinguishing closely
related T/F HCV lineages from sequences that evolved from a
single genome but shared early stochastic mutations. Importantly,
it allowed us to vary key assumptions regarding the contributions
of long-lived hepatocytes containing multiple generations of
replication complexes and assess the effects on sample-based T/
F virus enumeration. From this analysis, we adopted a conserva-
tive operational cut-off of .2 shared mutations per quarter
genome (,2500 bp) or .4 shared mutations per half genome
(,5000 bp) to distinguish T/F genomes in most cases of HCV
transmission from chronically infected individuals (see Methods).
In more complicated transmission scenarios, where the index case
was hypothesized to be either acutely infected or to have
experienced a viral genetic bottleneck due to antiviral drug
therapy, we applied both an empirical approach where a single
shared polymorphism could represent a distinct T/F viral genome
as well as the more conservative modeling approaches. Impor-
tantly, both empirical and model-based analyses predicted that
consensus sequences of low diversity lineages before the onset of
immune-driven positive selection coalesced to founder viral
genomes at or near the moment of transmission.
Identification and enumeration of T/F genomes
Figure 4 depicts ML phylogenetic trees and Highlighter plots of
viral 59 half genome sequences from two subjects, one typical of
Figure 2. Maximum-likelihood tree (ML) of HCV sequences from acute and chronic infection subjects. 59 quarter 1 genomesequences
(core, E1, E2) from acute (red) and chronic (blue) subjects are shown along with HCV genotype 1 to 7 reference sequences(gray). Bootstrap values
represent 100 repetitions in this and subsequent figures. The horizontal scale bar indicates 5% diversity.
doi:10.1371/journal.ppat.1002880.g002
Hepatitis C Virus Transmission
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chronic infection (WIMI4025, panel A) and one illustrating the
reduced genetic diversity characteristic of a subject productively
infected by a single viral genome (10051, panel B). Sequences from
the chronic subject showed broad genotypic heterogeneity with a
maximum inter-sequence diversity of 3.83% (mean 1.2%; median
1.21%; range 0.12–3.83%) typical of chronic infection (Table S1).
Sequences from the acute subject revealed a very different pattern
of diversification (Figure 4B). These sequences, which were derived
from the last sampled time point 21 days after the beginning of
documented viremia (see Figure 1), were extremely homogeneous
with a mean diversity of 0.03%, median diversity of 0.02%, and a
range in diversity of 0–0.19%. Nucleotide substitutions corre-
sponded to a near star-like phylogeny, although unlike most early
HIV-1 sequence sets they deviated from a Poisson distribution
(p,561025), a finding consistent with predictions of the HCV
adapted model. This deviation resulted from two sequences (2C3
and 2C2) that contained a single shared polymorphismat position
2197 and two other sequences (2A2 and 2B34) that contained a
different shared polymorphism at position 4344. The shared
polymorphism at position 2197 was a first position GAG to TAG
transversion that resulted in the introduction of a stop codon.
Surprisingly, the same nonsense mutation was found in the
identical position in two additional sequences (2B8 and 2B9) from
this subject in a plasma sample taken 12 days earlier (Genbank
Figure 3. Models of HCV and HIV-1 diversification in acute infection. Panels A and C depict patterns of HIV-1 replication and diversification
compared with HCV in panels B and D. The various generations of HIV-1 (panel C) and HCV (panel D) are indicated as filled dots to represent HIV-1
proviruses or HCV replication complexes. The symbol t indicates the time to sampling in units of provirus generations for HIV-1 (,2 days) and of
replication complex generations for HCV (,1 day). Whereas HIV-1 is produced only from the latest generation of provirus, HCV is produced from
replication complexes of all generations. In this model, the number of HCV replication complexes of generation g at time t is given by
t
g
 
. For HIV-1
each provirus of the same generation produces roughly equal numbers of descendant HIV viruses. The replication complexes of HCV produce widely
different number of descendant viruses. Panels A and B show the impact of this difference on the expected fraction of pairs of viruses, sampled at
various times, that share a given number of ancestors. For HCV, the number of pairs of viruses sampled at time t that share at least g generations is
given by
P t{g
n~1
t{n{1
g{1
 
2n{1 2n{1ð Þ. One sees that HCV viruses typically share 50% more generations of ancestors than HIV, and with the
estimated mutation rates, this means that they share about 3 times the stochastic mutation events expected in HIV.
doi:10.1371/journal.ppat.1002880.g003
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accession nos. JQ803586, JQ803587, JQ803590 and JQ803591).
We could be assured that these persistent but defective genomes
were authentic and did not result from cross-contamination of
amplicon sequences since each of the four sequences had
additional distinguishing nucleotide polymorphisms (e.g., compare
sequences 2C3 and 2C2 in Figure 4B) or were processed, PCR
amplified and analyzed on different days (e.g., 2C3 and 2C2 versus
2B8 and 2B9). Occasional shared polymorphisms are commonly
found in acute HIV-1 infection sequences and can be explained by
polymerase errors early in infection being retained in the
population [15,49], but for neither HIV-1 nor HCV would
nonsense mutations be expected to be retained unless they were
complemented by competent genomes [50,56,57]. Regardless, the
60 sequences depicted in Figure 4B coalesced to a single
unambiguous consensus, which we inferredto represent a likely
T/F virus in this subject. To explore if additional T/F sequence
lineages might have been overlooked due to inadequate sampling,
we sampled 243 additional 59 quarter genome sequences from this
subject at three earlier time points spanning a 19 day period
(Figures 1 and S2). Power calculations indicate that a sample size
of 60 sequences provides 95% likelihood of detecting variants
present at 5% in the population [15], whereas a sample size of 303
sequences provides 95% likelihood of detecting variants present at
1% prevalence. 43 of 46 (93%) of the sequences at the initial time
point were identical, and diversity increased with time (Figure S2).
Whether the 303 59 quarter genome sequences from the different
time points were considered separately or together, they
conformed to a near star-like phylogeny and coalesced to the
same T/F genome. Thus, we can conclude with a high level of
confidence that subject 10051 was productively infected by a single
virus whose sequence is represented by the consensus in Figure 4B
and S2.
Figure 5 extends the analysis of T/F HCV genomes to four
acutely infected subjects where sequences from sequential time
points revealed variable patterns of early viral diversity. In each
subject, sequences from the initial sample were more homoge-
neous than those from later time points, as expected in a model of
random accumulation of mutations. For subject 10021 (panel A),
19 of 24 (79%) sequences from the initial timepoint were identical.
For subject 10025 (panel B), 32 of 43 (74%) of initial sequences
were identical. The remaining sequences from this first time point
in each subject differed from the respective consensus sequences by
only 1 or 2 nucleotides. At the second and third sampling time
points 1–4 weeks later, an increasing proportion of sequences from
each subject differed from the respective consensus sequences by
as many as 3 or 4 nucleotides. Interestingly, in both samples rare
shared mutations became evident at later time points, again
consistent with predictions of the HCV adapted model. For
subjects 10021 and 10025, we thus concluded that the respective
consensus sequences corresponded to single T/F HCV genomes.
Of the 17 acutely infected subjects, four had evidence of
productive clinical infection by single viruses (Tables 1 and S2).
Panels C and D depict sequences from subjects 10012 and 10062,
each of whom had evidence of productive infection by more than
one genetically distinct virus based on the presence of multiple
discrete low diversity lineages whose consensus sequences differed
from each other by far more than the 2 nucleotides per quarter
genome cut-off. Importantly, unlike HIV-1 where viral recombi-
nation in acute and early infection is extremely common [12,16],
we found no evidence of inter-lineage recombination in HCV
sequences from these subjects or from any other subjects in this
study.We thus interpreted the consensus sequences of each low
diversity lineage in subjects 10012 and 10062 to correspond to a
unique T/F HCV genome, three for each subject. This represents
a minimum estimate, since deeper sampling could conceivably
identify additional T/F sequence lineages, although with 188–230
sequences analyzed there was a 95% likelihood of detecting
variants present at 2% in the population (Table S2). Figure 6
depicts sequences from subject 10029 where discrete low diversity
sequence lineages indicated clinical acquisition of a minimum of 9
T/F viruses. In 6 additional acutely infected subjects, clearly
distinguishable T/F lineages ranged from 3 to 13 per subject
(Figures S3, S4, S5, S6, S7, S8).Importantly, for all of the acutely
infected subjects described above, the numbers of T/F sequence
lineages identified by visual inspection using the cut-off of .2 per
quarter genome and .4 per half genome were nearly identical to
those inferred from the HCV adapted model of early virus
diversification using standard (maximum cut-off) or stringent
(average cut-off) assumptions (Table S2).
Evidence of acute-to-acute HCV transmission
Virus diversity in three acutely infected subjects (10003,
Figure 7; 10020, Figure S9A; 10016, Figure S9B) shared features
that distinguished them from the other 14 acute subjects. In each
case, maximum sequence diversity was relatively low (0.27%–
0.41%), consistent with recent infection. However, unlike in other
subjects, samples from 10003, 10020 and 10016exhibited many
closely related sets of sequences that shared unique polymor-
phisms, which appeared as multiple vertical ‘stripes’ in the
Highlighter plots and shared nodes in the phylogenetic trees
(Figures 7 and S9A,B). In subject 10003 (Figure 7), there were at
least 37 distinctsequence sets, and in subjects 10020 (Figure S9A)
and 10016 (Figure S9B) there were 10 and 15, respectively.
Although we recognized that occasional shared mutations are
predicted by the model and were found in samples from subjects
infected by single or few viruses with well-defined T/F sequence
lineages (e.g., see Figures 4B, 5 and 6), the high frequency of
unique shared mutations in subjects 10003 (Figure 7), 10020
(Figure S9A) and 10016 (Figure S9B) was quite unusual and led us
to hypothesize that most of the 10–37 distinct virus lineages
observed in these individuals resulted from discrete transmitted
viruses from individuals who themselves were recently infected by
a single virus or by closely related viruses. An alternative
hypothesis that we considered was that infection by single viruses
had occurred in subjects 10003, 10020 and 10016but was followed
by atypical diversification patterns not seen in any of the other
acutely infected subjects. Our strategy to distinguish between these
scenarios was both empirical and model-based. First, we observed
that the maximum Hamming distances, expressed as per cent
diversity, between the consensus sequences of the discrete
sequence sets (i.e., between potential T/F genomes) from subjects
10016, 10020 and 10003, were 0.21%, 0.28% and 0.35% (mean
0.28%; median 0.28%), respectively. These values exceeded the
maximum intra-lineage diversity (mean 0.12%; median 0.12%;
range 0.04–0.19%; p = 0.0051, Mann-Whitney test) found in all
lineages from all subjects in the initial ,6 weeks of infection.
These findings suggested acquisition of multiple distinct variants
from recently infected subjects, not evolution of viruses from single
transmitted variants. Secondly, we found that the multiple
sequence sets in subjects 10016, 10020 and 10003 were present
Figure 4. HCV diversity in chronic (WIMI4025)and acute (10051) subjects. 59 half genome sequences (core, E1, E2, p7, NS2 and NS3) from
WIMI4025 (A) and 10051 (B) are depicted by mid-point rooted ML phylogenies and Highlighter plots.
doi:10.1371/journal.ppat.1002880.g004
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from the initial sampling time points and did not accumulate over
time, again suggesting acquisition not evolution of the variants.
Thirdly, we noted that the linear distribution of shared nonsynon-
ymous nucleotide substitutions across the viral genomes in subjects
10016, 10020 and 10003 was not random but instead was
concentrated in regions of E1 and E2 (Figure S10) previously
associated with immune escape [41,42,58]. Inspection of the
amino acid substitutions in the E2 region of the putative T/F
genomes revealed combinations of different nonsynonymous
mutations in identical or neighboring positions in the primary
sequence that were unlikely to have occurred by chance
(probability estimates ,0.001). Since these subjects were sampled
very early after infection, well before antibody seroconversion
(Figure 1) or the onset of cellular immune responses [9,10], the
data suggest that the patterns of viral diversity observed in the
putative T/F viral genomes from subjects 10016, 10020 and
10003 were the consequence of acquisition of multiple variants
from transmitting individuals who themselves had become infected
in the preceding ,6 months and whose viral sequences had been
subjected to early epitope-focused immune selection.
We next applied our HCV adapted model of early virus
diversification to the sequences from the three subjects 10016,
10020 and 10003(Figures 8; S14–15). Under standard model
assumptions (maximum cut-off, see methods) for delineating T/F
lineages, transmission by at least 6–19 genetically distinct viruses
was necessary to explain the viral diversity observed in the three
subjects. Even under the most conservative model assumptions
(average cut-off), transmission of at least 2–9 distinct viruses was
required. Based on these findings, we conclude that the pattern of
viral sequence variation in subjects 10003, 10020 and 10016can be
most plausibly explained by acute-to-acute virus transmission.
Transmission of multiple NS3A drug resistant variants
The phylogenetic pattern of sequences from subject 106889
(Figure 9) was still more complicated than that of any of the other
16 acutely infected subjects. This subject exhibited a typical acute
infection viral kinetic profile with four sequential plasma samples
negative for HCV vRNA and antibody followed by rapid vRNA
ramp-up to nearly 46106 vRNA IU/ml (Figure 9 insert). These
plasma samples from subject 106889 were obtained in June and
July 2008 and were preceded by over 150 plasma collections from
this individual in 2003–2008, all of which were negative for HCV
RNA or antibody, proving this individual had incident infection.
Eighty-seven 59 half genome sequences were obtained from the
initial plasma vRNA positive time point (Figure 9). Maximum
diversity of these sequences was 1.03%, indicating multi-variant
transmission. Similar to subjects 10003, 10020 and 10016,
numerous discrete, low diversity sequence clades, many of which
were closely related to each other, were apparent in the
maximum-likelihood tree and Highlighter plot. Unlike sequences
from the other subjects, however, the distinct sequence sets in
106889 clustered with high bootstrap values into larger lineages
(color-coded in Figure 9). Thoseclades that contained sufficiently
large numbers of sequences for analysis (e.g., clades identified by
sequences 5.B.F9 and 5.02C22) exhibited a star-like phylogeny
and Poisson distribution of mutations (Table 1), indicating that
they had evolved very recently from discrete T/F genomes.These
findings suggested that subject 106889 had been infected by large
numbers of virusesfrom a chronically infected individual whose
HCV sequences had been subjected to a stringent genetic
bottleneck. A quite unexpected finding suggested a likely
explanation: 86 of the 87 sequences from subject 106889 were
found to contain two signature mutations in the NS3 protease gene
(V36M and R155K) that confer high level drug resistance to the
NS3 protease inhibitors Boceprevir and Telaprevir [7]. One of 87
sequences (sequence 02B11 in Figure 9) contained one of these
DAA resistance mutations (V36M). Since the combination of
V36M and R155K mutations is uncommon in treatment-naı¨ve
individuals [59], this result suggested that a transmitting partner to
106889 was chronically infected with HCV, was treated with an
investigational NS3 protease inhibitor, experienced a DAA-
induced viral population bottleneck followed by the emergence
of NS3 protease resistant variants, and as these variants
rebounded, transmitted multiple drug resistant variants directly
to subject 106889 or indirectly through a second acutely infected
individual. Under this scenario, where closely related sequences
differing by as few as one nucleotide would be expected to be
transmitted, we estimated by visual inspection of the phylogenetic
tree that as many as 30 or more T/F virus could have been
responsible for productive clinical infection (Table S2). By the
standard model analysis, 28 distinct T/F viral genomes were
necessary to account for the observed diversity. By the more
conservative model analysis, at least 16 distinct T/F genomes were
needed (Table S2).
Virus diversification from T/F genomes
The identification of T/F viral sequencesin 17 subjects provided
us with a unique opportunity for analyzing HCV sequence
evolution in natural human infection beginning at or near the
moment of virus transmission and extending through the
establishment of early viral load setpoint, and in some subjects,
antibody seroconversion. Among the 17 subjects, we identified a
total of 146 T/F genomes. As expected, all 146T/F sequences had
intact open reading frames for core, E1, E2, P7, NS2 and NS3.
Thirty T/F genomes had 5 or more identifiable progeny (range 5–
303; median 19) from which we could analyze molecular features
of sequence diversification in vivo using phylogenetic tools and
algorithms. A summary of this analysis is presented in Table 1.
Maximum intra-lineage diversity for the 17 subjects ranged from
0.04% to 0.19% (mean = 0.12%; median = 0.12%), which was
significantly lower than the maximum, mean and median viral
diversities observed in chronically infected subjects (3.83%, 2.27%
and 2.37%, respectively; p,0.0001, unpaired T-test with Welch’s
correction) (Tables 1 and S1; Figure S1). Evolved sequences
compared to their respective T/F genomes revealed low frequen-
cies of per nucleotide insertions (161026), deletions (361026) and
stop codons (161026). Transitions outnumbered transversions by
8.8 to 1, and when corrected for the number of available sites, by
18 to 1. The average dN/dS ratio was low at 0.39. The overall
mutation frequencyamong all 17 acute subjects uncorrected for
time from transmission or numbers of virus replication cycles was
1.461024. When sequences were analyzed in the context of an
agent-based stochastic model of virus diversification that incorpo-
rates estimated time from transmission and HCV specific
parameters of virusreplication, the mutation rate of HCV in vivo
was estimated to be 2.561025 per nucleotide per genome
replication [50]. We confirmed this low value by an analysis of
the nonsense codon frequency per nonsense mutation target site
Figure 5. HCV diversity in acute infection. ML trees and Highlighter plots of 59 quarter 2 genomesequences from four acutely infected subjects.
Sequences are color coded to reflect sampling time points indicated in Figure 1. Subjects 10021 (A) and 10025 (B) revealed productive clinical
infection by a single viruses whereas subjects 10012 (C) and 10062 (D) each showed infection by three viruses (v1–3).
doi:10.1371/journal.ppat.1002880.g005
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[50]. Progeny of T/F viruses sampled at the earliest time points
generally conformedto a star-like phylogeny and a Poisson
distribution of randommutations (Table 1), but at later time
points there were occasional deviations. Deviations from the
model were of three types: (i) shared polymorphisms resulting from
stochastic changes after the transmission event or from the
transmission of multiple closely related viruses; (ii) immune
selection or reversion in later samples at the time of antibody
seroconversion in a single subject 9055 (Figures S16, S17); (iii) rare
examples of short perfect inverted repeats, 3–20 nucleotides in
length, that resulted from template switching between double-
stranded RNA molecules in locations prone to RNA stem-loop
secondary structure (Figure S18). This latter finding, which was
found in 7 sequences out of 2922 analyzed,was observed in
samples from three different study subjects. Four of these strand
transfers occurred at the same location in the core gene.
Discussion
The present study provides new quantitative and qualitative
insights into HCV transmission and early diversification in
humans. Previous reports documented a virus population bottle-
neck associated with HCV transmission, but none of those studies
including ones based on 454 deep sequencing captured the broad
Figure 6. HCV diversity in acute subject 10029. MLtree and Highlighter plot of 59 quarter 1 genomesequences,color coded to reflect sampling
time points in Figure 1, reveal productive infection by 9genetically-distinct viruses.
doi:10.1371/journal.ppat.1002880.g006
Figure 7. HCV diversity in subject 10003.ML tree and Highlighter plot of 59 halfgenome sequences reveal many sets of closely related sequences
distinguished by unique shared mutations.
doi:10.1371/journal.ppat.1002880.g007
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range in multiplicity of infection or the full spectrum of genetic
diversity that exists among transmitted viruses. In our study of 17
acutely infected subjects, we could unambiguously identify and
determine the exact nucleotide sequences of one or more T/F
virus genomes in each subject. This was true for all subjects whose
HCV genomes were sequenced within the initial ,6–8 weeks of
infection; beyond that there were examples of immune selection
that confounded the identification of T/F virus genomes (Figures
S16 and S17). We estimated the multiplicity of infection (numbers
of T/F viruses leading to productive clinical infection) to range
from 1 to as many as 37 or more with a median of 4. These are
minimum estimates given our sampling limitations, although we
note that our median sampling depth of 151 sequences (Table 1)
afforded us a 95% likelihood of detecting variants present at 2%
prevalence [15]. In subjects productively infected by lower
numbers of viruses (,10), where the progeny of each transmitted
Figure 8. HCV diversity analysis in subject 10016 suggests acute-to-acute transmission. Highlighter plot and neighbor-joining tree of 59
quarter 1 genome sequences. Visualization of 15 potential T/F viral lineages distinguished by unique shared mutations is indicated by lower case
(blue) letters. Model estimates of T/F virus lineages using maximum (red) and average (green) cut-offs reveal 10 and 4 potential T/F virus lineages,
respectively, based on increasingly stringent model assumptions (see text).
doi:10.1371/journal.ppat.1002880.g008
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virus is repeatedly sampled, our estimates (Tables 1 and S1) are
likely to be an accurate and precise measure of the number viruses
that result in productive infection. In subjects infected by higher
numbers of viruses, especially in the setting of acute-to-acute
transmission where transmitted viruses are expected to differ by as
few as one nucleotide, the accuracy of our estimates are necessarily
less. This is because we could not sample deeply enough due to
practical constraints of single genome sequencing of quarter and
half genomes, and because we could not distinguish between
transmitted viruses that differ by one or few nucleotides from
single variant transmission followed by early stochastic mutations.
However, based on the striking differences in diversity patterns
that we observed between subjects with chronic-to-acute versus
apparent acute-to-acute transmission, we suspect that the actual
numbers of T/F viruses in subjects 10016, 10020, 10003 and
106889 approximate or exceed our estimates of 15, 10, 37 and 30
T/F genomes, respectively (Tables 1 and S2).
The broad range in numbers of T/F viruses responsible for acute
HCV infection in our cohort must reflect the different transmission
routes and risk practices ofsource plasma donors. Ostensibly, such
individuals should be at low risk of acquiring HCV infection since
they are qualified as regular source plasma donors only after extensive
pre-enrollment screening that consists of medical histories, physical
examinations and behavioral questionnaires designed specifically to
eliminate from the donor pool individuals at risk for HCV, HBV or
HIV infection (http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/default.htm). Howev-
er, self-reporting of risk behaviors among paid plasma donors is
admittedly imperfect [60]. Thus, it is likely that the subjects in the
present study represent the broad clinical spectrum of community-
acquired HCV infection in the United States, which includes
injection drug users, men who have sex with men, heterosexuals, and
possibly, household contacts of HCV infected individuals.
Our findings regarding the multiplicity of human infection by
HCV are quite different from those obtained by 454 pyrose-
quencing in seven acutely infected subjects reported by two
different investigative groups where the range in T/F viruses was
one to four with a median one [19,43]. Our findings are also
substantially different from estimates from other reports that
employed reverse transcription, bulk PCR amplification, popula-
tion sequencing or molecular cloning followed by sequencing
[20,23,25,30,38,41,42].The latter studies showed that acutely
infected subjects exhibited a spectrum in HCV sequence diversity
that could at best be interpreted qualitatively as reflecting ‘few-
variant’ versus ‘multi-variant’ transmission. We also note a recent
study that used conventional bulk PCR amplification, cloning and
sequencing to analyze acute and early HCV sequences consisting
of a 225 bp hypervariable region of env from 10 acute infection
subjects following IDU, sexual or nosocomial exposures [28].
Thisreportdescribed perplexing findings: 7 of 10 acutely infected
Figure 9. HCV plasma vRNA kinectics and diversity in subject 106889 reveals multivariant transmission of drug resistant mutants.
vRNA kinetics (inset), ML phylogenetic tree, and Highlighter analysis of 59 half genome sequences from the initial vRNA positive sample (circled).
Sequences fall into distinct lineages (color-coded) with high statistical bootstrap support. All inferred T/F genomes contained V36M and R155K NS3
protease drug resistance mutations.
doi:10.1371/journal.ppat.1002880.g009
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subjects seemed to harbor more than one HCV genotype
andsequential sequences obtained from these subjects a median
of 17.5 days apart throughout the acute infection period suggested
fluctuations in the prevalence of different HCV genotypes,
subtypes and clades. These findings are at odds with our results
(Figures 2, 4–9, S2, S3, S4, S5, S6, S7, S8, S9 and S14, S15, S16)
and those of most other studies [24].
The SGA-direct amplicon sequencing strategy used in the
present study represents a substantial advance in sensitivity and
molecular resolution for distinguishing closely and distantly related
T/F HCV genomes and their evolving progeny. Studies of HCV
specific CTL recognition and escape [20,25,61,62], neutralizing
antibody recognition and escape [41,42], and DAA drug
resistance development [7] have previously been performed
without a precise identification of T/F viral genomes and future
studies may benefit from such an approach. We could readily
distinguish evolving viral lineages that differed from the T/F
genome by just 1 nucleotide in 5,000 (0.02%) at sites under
selective pressure (Figures S16–17). This discriminating power
further revealed evidence of acute-to-acute virus transmission in
three subjects (Figures 7, 8 and S9) and DAA drug-induced viral
genetic bottlenecking in a donor to a fourth acutely infected
subject(Figure 9). This exquisite sensitivity in distinguishing T/F
virus genomes and their progeny stands in contrast to the 454-
based approaches, which were unable to distinguish between T/F
viruses that differed by less than 2.5% [43] and bulk PCR-clone-
sequencing methodsthat used a cutoff of 3% diversity to
distinguish homogeneous from heterogeneous virus transmission
[23]. Both of the latter methods are further confounded by the
potential for Taq polymerase-mediated strand transfers leading to
recombination artifacts in finished sequences [15,19,63].
The ability to identify actual T/F viral sequences and to track
virus diversification from these sequences with single nucleotide
resolution provided a unique opportunity to assess HCV sequence
evolution in vivo. Virus diversification from discrete T/F viruses
was generally star-like and conformed well to our HCV adapted
model of early virus diversification. The finding of only a single
instance of potential CTL escape or reversion among 17 acutely
infected subjects at the last sampling time point is consistent with
previous reports indicating substantial delays in the onset of
adaptive immunity to HCV [9,10]. The overall nucleotide
substitution frequency that we observed among all subjects and
including all sampling time points was 1.461024. This substitution
frequency is different from the mutation rate since it does not
account for time, numbers of replication cycles, or different modes
of HCV replication (linear versus geometric) [3,57,64], nor does it
account for nucleotide substitutions introduced by the MuLV
polymerase (Superscript III) during cDNA synthesis. The latter is
estimated to occur at a frequency as low as 261026 [65] and thus
likely contributes negligibly to the mutation frequencies observed
in the present study. Consistent with this interpretation were our
results of single genome sequencing performed on the earliest
vRNA positive plasma sample from subject 10051 where we found
that 43 of 46 59 quarter 1 genome sequences were identical (Figure
S2). Among all 46 sequences, there were only four nucleotide
substitutions in 100,050 nucleotides. This corresponds to a
combined substitution frequency for the HCV polymerase and
the Superscript III MuLV polymerase of 461025, Again, thisresult
does not account for the numbers of HCV replication cycles
occurring between the moment of virus transmission and the time
point of sampling, which in this case was very early during the viral
ramp-upperiod when the plasma virus load was approximately
10,000 vRNA molecules/ml (Figure 1). In an accompanying
report [50], we describe a new stochastic model of HCV
replication and diversification that provides for a more precise
estimation of the in vivo HCV RdRp error rate, which was found to
be ,2.561025 per base per generation. This is lower than
previous reports for HCV [56,57] and comparable to the RT error
rate of HIV-1 [57,66].
We found a low dN/dS ratio consistent with early negative or
purifying selection and a strong 18 to 1 mutational bias for
transitions over transversions in acute infection. The latter finding
is consistent with a recent report by Gotte and colleagues [67] who
studied sequence evolution in chronically infected subjects and in
vitro where a strong preference for G:U/U:G mismatches was
observed for recombinant HCV RdRp. A mutational bias favoring
transitions may be a factor besides RdRp error rate that influences
the rate of development of DAA resistance mutations [67].
Importantly, we found no evidence of viral recombination in any
subject, which would have been plainly evident in those subjects
infected by multiple genetically diverse viral genomes (Figures 5C,
D; 6; S3–9). The absence of recombination distinguishes HCV
from HIV-1, where early recombination is widespread [12,16,46],
but is consistent with molecular epidemiological data that suggest
that HCV recombination is rare [68–71]. In addition, the failure
to find plus-plus strand recombination in any of the sequences in
the present report shows that strand switching by the MuLV
reverse transcriptase (RT) in vitro must be extremely rare. This is
important because it demonstrates that MuLV RT-mediated
recombination does not confound single genome sequence
analyses of HCV or other RNA viruses including HIV-1 andSIV
[15,18,51]. On the other hand, we did observe seven examples of
template switching between plus and minus strands of double-
stranded HCV RNA templates (Figure S18). We could not
determine if this resulted from strand switching by MuLV RT in
vitro or by HCV RdRp in vivo. We note that Branch and colleagues
[72] recently reported high levels of double-stranded HCV RNA
in hepatic tissue, thus providing a plausible source of dsRNA for
the observed template switching events.
A surprising finding of the current study was evidence of acute-
to-acute HCV transmission in a relatively high proportion (3 of 17)
of subjects. The acute infection period of HCV, like that of HIV-1,
is characterized by very high plasma virus loads, absence of
neutralizing antibodies, and rapid expansion of biologically fit
virus populations that are homogeneous relative to the respective
T/F virus genomes [22,26,27]. For HIV-1, the acute and early
infection period has been shown to be associated with hyper-
transmissibility with epidemiological studies and epidemic model-
ing indicating substantial enhancement in spread of the virus as
long as six months post-transmission [73–76]. In the simian
immunodeficiency virus (SIV) – Indian rhesus macaque transmis-
sion model, virus from acute infection plasma is up to 750-fold
more transmissible on a per virion basis than is virus from chronic
infection plasma [77]. To our knowledge, a clinical predilection
for acute-to-acute HCV transmission has not previously been
reported. In addition to the three subjects whom we identified with
putative acute-to-acute HCV transmission, an argument can be
made for an additional potential case in subject 10017 in whom
distinct subsets of closely related T/F sequences were found within
a context of high overall sequence diversity (e.g., see lineages v1
and v3; Figure S8). In this example, a plausible scenario is that a
virus ‘donor’ to subject 10017 was acutely infected by multiple
genetically-diverseviruses and that multiple progenyrepresenting
several of these lineages were transmitted. The implication of these
findings is that if the acute period of HCV infection is
characterized by hyper-infectiousness as is the case for HIV-1, it
could be a previously unrecognized but important contributing
factor to the spread of HCV, potentially contributing to a recently
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described emerging HCV ‘epidemic’ in HIV-1 positive men who
have sex with men [78,79]. A limitation in our evidence
supporting ‘acute-to-acute’ infection is that our study design did
not allow us to identify paired donors and recipients of virus in
order to analyze virus transmission directly. Future viral sequenc-
ing studies involving social networks of HCV transmission partners
[80], or analyses of cryopreserved plasma specimens from
previously conducted acute-to-acute human-to-chimpanzee HCV
transmission studies [81], can provide corroborative evidence. We
notethat there is precedent for phylogenetic linkage of HCV
sequences in a human-to-human transmission case where clinical
epidemiologic linkage between donor and recipient was estab-
lished [42].
Still another surprising observation in this study was transmis-
sion of what we estimated to be as many as 30 NS3 protease-
resistant viruses to subject 106889 (Figure 9). These mutations
(V36M and R155K) confer high level resistance to both
Boceprevir and Telaprevir, which were used in clinical trials near
the time when 106889 samples were collected. Recently, we
performed single genome sequencing of plasma viral RNA from
subjects before and after treatment with a next generation
investigational HCV protease inhibitor and observed viral genetic
bottlenecking closely resembling that found in subject 106889
(unpublished data). To our knowledge, the data from subject
106889 is the first example of high multiplicity DAA drug resistant
virus transmission, and the findings here illustrate how transmis-
sion of DAA resistant mutants can be deciphered with single
genome specificity and sensitivity.
The identification of T/F genomes of HCV, HIV-1 [18], SIV
[51] and potentially other RNA viruses by single genome
sequencing is an enabling experimental strategy that captures
molecular entities that are wholly sufficient and responsible for
productive clinical infection and disease causation. In an
accompanying report [50], we use sequences derived by this
approach to analyze and mathematically model the early
dynamics of HCV replication and diversification in acutely
infected humans and derive new estimates of the in vivo mutation
rate of HCV. A second application of the single genome
sequencing method is to reveal through enumeration of T/F
genomes, the challenge that vaccine candidates face in attempting
to prevent or constrain HCV transmission. In a third application
of the method, we previously demonstrated for HIV-1 that single
genome sequencing allows for the molecular identification, cloning
and biological characterization of full-length T/F genomes and a
comprehensive proteome-wide analysis of autologous, strain-
specific patterns of cytotoxic T-cell and neutralizing antibody
responses [13,18,82–84]. By demonstrating that early HCV
diversification generally conforms to a model of essentially random
virus evolution where sequences coalesce to distinct, unambiguous
T/F genomes, the present study has taken the first critical steps to
demonstrate the feasibility of similar genome-wide analyses for
HCV. An intriguing possibility is that full-length T/F HCV
genomes, which by definition possess nucleotide and amino acid
sequences sufficient for efficient in vivo replication in humans, can
be identified, molecularly cloned and expressed for biological
analyses in cell culture and animal models.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. It was approved by the Institutional
Review Boards of the University of Pennsylvania, the University of
Alabama at Birmingham and Duke University. Subjects provided
written informed consent for the collection of blood samples and
subsequent analyses.
Study subjects
Plasma samples were obtained from 17 subjects with acute
HCV infection. These subjects were regular source plasma donors
(ZeptoMetrix, Inc.; SeraCare, Inc.) who were HCV and HIV-1
antibody negative but who became HCV infected sometime in the
course of their twice-weekly plasma donations as evidenced by the
development of HCV viremia on sequential viral RNA testing
(Figure 1). The subjects were asymptomatic throughout the
collection period and did not receive anti-HCV treatment. By
the time of the last sample collection, 5 of the subjects had
seroconverted to HCV antibody positivity. Plasma samples from
14 patients from University of Alabama at Birmingham with
chronic, treatment-naı¨ve HCV infection were obtained as
controls.
HCV RNA and antibody assays
Plasma samples were tested for HCV RNA and antibodies by a
battery of commercial tests. These included Roche COBAS
AmpliPrep/COBAS Taqman HCV vRNA assay; ABBOTT Anti-
HCV 3.0 Assay and ORTHO Enhanced SAVe Anti-HCV 3.0
Assay. HCV vRNA analyses were performed according to
manufacturer’s specifications (http://www.accessdata.fda.gov/
cdrh_docs/pdf6/P060030c.pdf) in a CLIA certified laboratory
with all assay controls meeting predetermined parameters for assay
sensitivity and specificity and with a dynamic linear range of 43 to
6.96107 vRNA IU/ml.
Viral RNA extraction and cDNA synthesis
For each plasma sample, approximately 100,000 viral RNA
copies were extracted using the QiagenBioRobot EZ1 Worksta-
tion with EZ1 Vrius Mini Kit v2.0 (Qiagen, Valencia, CA). RNA
was eluted and immediately subjected to cDNA synthesis. Reverse
transcription of RNA to single stranded cDNA was performed
using MuLV (SuperScript III) reverse transcriptase using methods
recommended by the manufacturer (Invitrogen Life Technologies,
Carlsbad, CA). Briefly, each cDNA reaction included 16 RT
buffer, 0.5 mM of each deoxynucleoside triphosphate, 5 mM
dithiothreitol, 2 units/ulRNaseOUT (RNase inhibitor), 10 units/
ul of SuperScript III reverse transcriptase, and 0.25 uM antisense
primer. The antisense primers were designed specifically for
different genotype. 1.NS4A-R1 59- GCACTCTTCCATCT-
CATCGAACTC -39 (nt 5451–5474 H77 (accession number
NC_004102)) for genotype 1, 2NS2-R1 59-CCCCAGACGAT-
GACTTTCTTCTCCAT-39 (nt 5445–5467 H77) for genotype 2
and 3aNS3-R2V2 59–TTACTTCCAGATCAGCTGACA-39 for
genotype 3. The reverse transcription reaction was carried out at
50uC for 60 minutes followed by an increase in temperature to
55uC for an additional 60 minutes. The reaction was then heat-
inactivated at 70uC for 15 minutes and then treated with 0.1 U/ul
RNaseH at 37uC for 20 minutes. The newly synthesized cDNA
was used immediately or kept frozen at 280uC.
Single genome amplification
cDNA was serially diluted and distributed among wells of
replicate 96-well plates (Applied Biosystems, Foster City, CA) so as
to identify a dilution where PCR positive wells constituted less
than 30% of the total number of reactions. At this dilution, most
wells contain amplicons derived from a single cDNA molecule.
This was confirmed in every positive well by direct sequencing of
the amplicon and inspection of the sequence for mixed bases
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(double peaks), which would be evidence of priming from more
than one original template or the introduction of PCR error in
early cycles. Any sequence with evidence of mixed bases was
excluded from further analysis. PCR amplification was carried out
in the presence of 16High Fidelity Platinum PCR buffer, 2 mM
MgSO4, 0.2 mM of each deoxynucleoside triphosphate, 0.2 uM of
each primer, and 0.025 units/ul Platinum Taq High Fidelity
polymerase in a 20 ul reaction (Invitrogen, Carlsbad, CA). The
nested or hemi-nested primers for generating 59 half or 59 quarter
genome from different genotypes included: (1) 59 half genome of
genotype 1: 1st round sense primer 1.core.F1 59-ATGAGCAC-
GAATCCTAAACCTCAAAGA-39 (nt 342–368 H77) and 1st
round antisense primer 1.NS4A.R1 59-GCACTCTTCCATCT-
CATCGAACTC-39 (nt 5451–5474 H77), 2nd round sense primer
1.core.F2 59- TCAAAGAAAAACCAAACGTAACACCAACC-
G-39 (nt 362–391 H77 and 2nd round antisense primer
1.NS3A4A.R2 59- AGGTGCTCGTGACGACCTCCAGG-39
(nt 5297–5319 H77); (2) 59 quarter genome of genotype 2: 1st
round sense primer 2.core.F1 59- ATGAGCACAAATCC-
TAAACCTCAAAGA-39 (nt 342–368 H77) and 1st round
antisense primer 2.NS2.R1 59- CCCCACACAATGACC-
TTCTTCTCCATTG -39 (nt 5445–5467 H77), 2nd round sense
primer 2.core.F2 59- AATCCTAAACCTCAAAGAAAAACC-
AAA -39 (nt 351–377 H77) and 2nd round antisense primer
2.NS2.R2 59- GGGGAGAGGTGGTCATAGATGTAA -39; (3)
59 half genome of genotype 3: 1st round sense primer 3a.core.F1
59- ATGAGCACACTTCCTAAACCTCAAAGA -39 and 1st
round antisense primer 3aNS3-R1V2 59-TTACTTCCAGAT-
CAGCTGACA-39, 2nd round sense primer 3a.core.F2 59-
TCAAAGAAAAACCAAAAGAAACACCATCCG -39 and 2nd
round antisense primer PCR 3a.NS3-R2V2 59-TTACTTCCA-
GATCAGCTGACA -39. PCR was performed in MicroAmp 96-
well reaction plates (Applied Biosystems, Foster City, CA) with the
following PCR parameters: 1 cycle of 94uC for 2 min; 35 cycles of
a denaturing step of 94uC for 15 s, an annealing step of 58uC for
30 s, an extension step of 68uC for 5 min, followed by a final
extension of 68uC for 10 min. The product of the 1st round PCR
was subsequently used as a template in the 2nd round PCR under
same conditions but with a total of 45 cycles. Amplicons were
inspected on precasted 1% agarose E-gels 96 (Invitrogen Life
Technologies, Carlsbad, CA). All PCR procedures were carried
out under PCR clean room conditions using procedural safeguards
against sample contamination, including pre-aliquoting of all
reagents, use of dedicated equipment, and physical separation of
sample processing from pre- and post-PCR amplification steps.
DNA sequencing
PCR amplicons were directly sequenced by cycle-sequencing
using BigDye terminator chemistry and protocols recommended
by the manufacturer (Applied Biosystems; Foster City, CA).
Sequencing reaction products were analyzed with an ABI 3730xl
genetic analyzer (Applied Biosystems; Foster City, CA). Both DNA
strands were sequenced using partially overlapping fragments.
Individual sequence fragments for each amplicon were assembled
and edited using the Sequencher program 5.0 (Gene Codes; Ann
Arbor, MI). Inspection of individual chromatograms allowed for
the identification of amplicons derived from single versus multiple
templates. The absence of mixed bases at each nucleotide position
throughout the entire 59 half or quarter genome sequences was
taken as evidence of amplification from a single viral RNA/cDNA
template. This quality control measure enabled us to exclude from
the analysis amplicons that resulted from PCR-generated in vitro
recombination events or Taq polymerase errors and to obtain
multiple individual sequences that proportionately represented
those circulating HCV virions.
Sequence alignments
All the sequences alignments were initially made with ClustalW
and then hand-checked using MacClade 4.08 to improve the
alignments according to the codon translation. All 2922 59 half or
quarter-genome sequences from acute and chronic patients were
deposited in GenBank and edited alignments can be accessed at
http://www.hiv.lanl.gov/content/sequence/hiv/user_alignments/
Li2012.html.
Sequence diversity analysis
Two thousand three 59 half genomes and 919 59 quarter
genomes were amplified by SGA-direct amplicon sequencing from
the 31 subjects. Half genome sequences were generated so as to
obtain longer sequences for linkage analyses, whereas quarter
genome sequences were generated to enhance sensitivity of
amplification from early samples with lower viral loads. Among
the 3168 amplicons generated, the sequences of 2922 were
unambiguous at every position. The other 246 amplicons
contained one or more ‘‘double peaks’’ representing mixed bases
and these were discarded and not included in the analysis. The
median number of sequences analyzed per time point was 54
(mean = 54; range = 5–122) for acutely infected subjects and 25
(mean = 27; range = 13–44) for chronically infected subjects. A
total of 2922 sequences from all 17 acutely-infected and 14
chronically-infected subjects were analyzed using phylogenetic tree
analysis together with a sequence visualization tool, Highlighter
(www.HIV.lanl.gov), that allows tracing of common ancestry
between sequences based on individual nucleotide polymorphisms.
Phylogenetic trees were generated by maximum likelihood
methods using PhyML [85] or RAxML-VI-HPC [86]. For
subjects productively infected by more than one T/F virus,
lineages contained more than 5 closely related sequences were
included in the lineage diversity analyses. Lineage-specific
sequences were analyzed by the Poisson Fitter program (www.
HIV.lanl.gov).
Mutation rate calculation
A total of 30 T/F lineages from 17 acutely-infected subjects
were analyzed. Each sequence within the lineage was compared
with the T/F virus sequence of that lineage. The insertion,
deletion, transition and transversion frequencies were counted
manually or by computer program. The rates were calculated by
taking the ratio of each frequency number and the total number of
nucleotides of all the sequences within that lineage.
Synonymous and non-synonymous substitution rate
analysis
The SNAP program (www.HIV.lanl.gov) was applied to the
codon-aligned sequences of each T/F lineage. Within each
lineage, the number of synonymous and nonsynonymous substi-
tutions were derived by comparing to the T/F viral sequences.
The accumulation rates of synonymous substitutions per potential
synonymous site and nonsynonymous substitution per potential
nonsynonymous site were compared to screen for positive
selection.
Mathematical models and algorithms for estimating
numbers of T/F variants
Two mathematical models were used to analyze early HCV
sequence diversity. The first was originally designed for HIV-1 and
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has been previously described in detail [15,48,49]. The second is a
simplified deterministic model that accounts for the essential
differences in replication dynamics between HCV and HIV-1,
taking into account HCV’s life cycle, that HCV replication occurs
via a cytosolic replication complex, and that there can be many
replication complexes continuously producing viruses from a long-
lived infected cell. In this model, each HCV replication complex
was assumed to give rise to a new replication complex at regular
intervals by undergoing two RdRp copying events. These
complexes, which may reach 40 per cell [53], were presumed to
persist and produce viruses for the entire duration of the acute
infection sampling period. Because of the sequential creation of the
complexes, those at the same generation depth have widely
varying number of descendants, unlike the situation in HIV
(Figure 3). An average pair of HCV viruses then has a later most
common ancestor than does HIV. As a result, the model predicts
that sequences with a small number of shared mutations can arise
in a subject at detectable frequencies prior to the onset of immune
selection. This translates to an expectation of about 3 times larger
numbers of stochastically shared mutations in HCV than in HIV,
with the potential to violate the star-like hypothesis more often.
Furthermore, the persistence of HCV replication complexes of all
generations means that, in contrast to the situation in HIV, the
Poisson distribution is not necessarily a good model for inter-
sequence distances prior to selection, and sequences with distances
that deviate from Poisson distribution canbe derived from a single
T/F viral genome. Our simple model of HCV diversification
accounts for these issues and is amenable to an analytical
approach. At the same time, the numerical results from the
simplified model are consistent with those from a more detailed
agent based stochastic model of early HCV infection that we
present in an accompanying paper [50].
The implementation of the clustering algorithm works on a
phylogenetic tree describing the evolutionary relations between
these sequences and aims to identify monophyletic clusters that
could reasonably have arisen by evolution in the infected
individual. The modeling in Ribeiro et al. [50] shows that these
clusters should satisfy two separate criteria: (a) the total number of
mutations that could have accumulated is limited by the mutation
rate of the virus and the generation time, and (b) the number of
mutations shared by distinct sequences from a single T/F virus is
related by coalescent theory to the growth and stabilization of viral
load in these acute infections. Starting at the tips of the
phylogenetic tree, our algorithm identifies the largest clusters that
are consistent with these two criteria. Following from (a), every
replication complex present in the body produces a new
generation of replication complexes about once a day. Following
from this, at time t days into infection, the most divergent
replication complex is t generations from the founder, but most
replication complexes are of generation t/2. We therefore split the
clusters whose average divergence is larger than expected from this
scenario. Following from (b), if one samples approximately 30–100
sequences in the initial weeks of infection prior to the onset of
immune selection, 1–10 pairs of sequences are expected to
coalesce 4–7 generations after the T/F virus.Assuming a mutation
rate of 2.561025 per base per generation [50], this corresponds to
a probability of more than 5% of seeing 3–4 shared mutations in
5000 bases. Thus, to be conservative in our model estimates of
minimum numbers of T/F genomes, wedefined clusters of
sequences as having .4 shared mutations in a half genome, or
.2 in a quarter genome, as unambiguously to have arisen from a
different founder variant.
In the case of acute-to-acute infections, however, the average
divergence is a very weak measure for delineating the clusters. In
particular, transmission of one or a few highly divergent sequences
affects the average little, and they are often not identified as
separate variants when they are likely to represent a distinct
founder. Thus, mean diversity is a robust measure but occasionally
allows one or a few highly divergent sequences to be counted as a
part of the cluster. To provide an estimate of the number of T/F
variants that takes this into account, we also calculated the number
of clusters by implementing a threshold on the most distant tip
from the inferred ancestor for each cluster, splitting clusters based
on the maximum distance that is improbable. Though this
provides a better overall estimate for the number of clusters, such
extreme-value statistics are more affected by the approximations
made in going from the fully stochastic to the deterministic model.
We verified that the main conclusions of this paper, including the
identification of three subjects as cases of acute-to-acute transmis-
sion, follow from either of the two methods of identifying T/F
lineages. Both of these methods provide a minimum estimate for
the number of T/F viruses for two reasons. First, the number of
shared mutations we have allowed within a cluster provides a
highly conservative criterion and lineages could still contain closely
related but distinct transmitted viral sequences, a situation made
likely by our identification of probable cases of acute-to-acute virus
transmission. Second, finite depth of sequencing means we might
miss T/F clusters that are represented by a small fraction of
sequences. To estimate the impact of this second scenario, we
performed direct power calculations as previously described [15]
to assess the likelihood of missing infrequent T/F sequence
lineages based on sampling depth.
Finally, acute samples are often very homogeneous and can
have conflicting phylogenetic signals, and these calculations rely
on the phylogenetic tree being a description of the true
evolutionary relations. In cases of infection with two highly
divergent strains, the descendants of the two strains form distant
outgroups from each other, and homoplasy on the long branch
linking the two may root the individual clusters suboptimally. To
avoid this problem, our algorithm looks for long branches (longer
than 30 mutations), deletes them, and applies the rest of the
algorithm to each of the then disconnected clusters.After
identifying these clusters, the roots of each of these is chosen as
tentative transmitted founder viruses. The paths in the phyloge-
netic tree between these roots represent evolution that happened
prior to infection, whereas the paths linking the roots to the tips
indicate within host evolution. Occasionally, we find overlap
between the two sets of paths indicating convergent evolution
between the donor and the recipient infected individuals. Since
convergent evolution is unlikely, we further subdivide the
previously found clusters to avoid this.After finding the optimal
clustering at each time point, the results are mapped on to a tree of
all the sequences obtained at various time points from the same
individual. The overall number of clusters is then found by
merging clusters from different time points that interleave, and
leaving the other clusters as distinct. In the scenario of early
infection when there are very few mutations, the tree can be
ambiguous because of single conflicting mutations causing
polytomies; while this could theoretically make the number of
transmitted variants ambiguous, this was not the case in our
analysis of this sequence set.Codes written in C that implement
these two clustering strategies (using either maximum or average
distances to define clusters) are available at http://www.santafe.
edu/,tanmoy/programs/HCV/.
Statistical analyses and power calculations
Standard descriptive statistics including Mann-Whitney and
unpaired T-tests with Welch’s correction were employed and
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identified throughout the text. Power calculations to estimate the
likelihood of detecting rare sequence variants based on sampling
depth were performed as previously described [15]. Estimates of
the probability that observed clusters of nonsynonymous muta-
tions in the Env E2 coding region of putative T/F viral genomes
from subjects 10003, 10016 and 10020 could have occurred by
chance were performed with a binomial expansion as previously
reported [87]. We considered ten codon windows because this
could generally span the observed clusters as well as typical T-cell
epitopes and potential linear neutralizing antibody epitopes. From
the binomial expansion, the probability of seeing at least the
observed number (k) of clustered mutations within a single 10-mer
is:
r 
Xm
k0~k
m
k0
 
pk
0
1{pð Þm{k0
where r is the number of potential 10-mers, m is the total number
of mutations relative to the consensus, and p is the probability that
a mutation falls by chance in any particular 10-mer. We calculated
the probability only for k9= k, since the results for all k9.k are very
much smaller and can be ignored. Only nonsynonymous
mutations were included in the analysis. Within the 10-mers of
interest, but not elsewhere along the alignment, different amino
acid substitutions and combinations of substitutions were identified
and analyzed.
Supporting Information
Figure S1 Maximum diversity of discrete HCV se-
quence lineages from acute infection subjects versus
maximum sequence diversity in chronic subjects. Prima-
ry data are derived from Tables 1 and S1. Mean (695% CI) values
are represented by horizontal lines. Differences between the two
groups were highly significant (p,0.0001; unpaired T-test with
Welch’s correction), reflecting the recent and remote diversifica-
tion histories of acute and chronic sequences, respectively.
(PDF)
Figure S2 HCV diversity in acute subject 10051. 59
quarter 1 genomesequences are color coded in orange, green, blue
and black in chronological order to reflect sampling time points in
Figure 1 and are represented in a ML tree and Highlighter plot.
Sequences show evidence of productive clinical infection by a
single virus. The horizontal scale bar indicates genetic distance.
(PDF)
Figure S3 HCV diversity in acute subject 10024. 59
quarter 1 genomesequences are color coded in blue, green and
black in chronological order to reflect sampling time points in
Figure 1 and are represented in a ML tree and Highlighter plot.
Sequences show evidence of productive clinical infection by at
least 6 T/F viruses. Bootstrap values are indicated and represent
100 repetitions. The horizontal scale bar indicates genetic
distance.
(PDF)
Figure S4 HCV diversity in acute subject 6213. 59 half
genomesequences are represented in a ML tree and Highlighter
plot. Sequences show evidence of productive clinical infection by
at least 3 T/F viruses. Bootstrap values are indicated and represent
100 repetitions. The horizontal scale bar indicates genetic
distance.
(PDF)
Figure S5 HCV diversity in acute subject 6222. 59 half
genomesequences are represented in a ML tree and Highlighter
plot. Sequences show evidence of productive clinical infection by
at least 4 T/F viruses. Bootstrap values are indicated and represent
100 repetitions. The horizontal scale bar indicates genetic
distance.
(PDF)
Figure S6 HCV diversity in acute subject 10004. 59
quarter1 genomesequences are represented in a ML tree and
Highlighter plot. Sequences show evidence of productive clinical
infection by at least 3 T/F viruses. Bootstrap values are indicated
and represent 100 repetitions. The horizontal scale bar indicates
genetic distance.
(PDF)
Figure S7 HCV diversity in acute subject 10002. 59 half
genomesequences are represented in a ML tree and Highlighter
plot. Sequences show evidence of productive clinical infection by
at least 13 T/F viruses. Bootstrap values are indicated and
represent 100 repetitions. The horizontal scale bar indicates
genetic distance.
(PDF)
Figure S8 HCV diversity in acute subject 10017. 59
quarter 1 genomesequences are color coded in red, orange, green,
blue and black in chronological order to reflect sampling time
points in Figure 1 and are represented in a ML tree and Highlighter
plot. Sequences show evidence of productive clinical infection by
at least 4 T/F viruses. Bootstrap values are indicated and represent
100 repetitions. The horizontal scale bar indicates genetic
distance.
(PDF)
Figure S9 HCV diversity in acute subjects 10020 and
10016. 59 quarter1 genome sequences from subject 10020 (panel
A) and 10016 (panel B) are depicted by ML tree and Highlighter
plots. Many sets of closely related sequences distinguished by
unique shared mutations are evident. Bootstrap values represent
100 repetitions.
(PDF)
Figure S10 Nonsynonymous and synonymous muta-
tions in HCV sequences from acute subjects 10003,
10020 and 10016. Highlighter plotsof 59 half or quarter1
genomesequences are color coded to denote nonynonymous
(red) and synonymous (green) mutations for subjects 10003 (panel
A), 10020 (panel B) and 10016 (panel C).
(PDF)
Figure S11 Amino acid alignment of the HCV Env
coding region of acute subject 10003. The H77 reference
sequence is shown at the top. Nonrandom concentrations of
nonsynonymous mutations are evident.
(PDF)
Figure S12 Amino acid alignment of the HCV Env
coding region of acute subject 10020. The H77 reference
sequence is shown at the top. Nonrandom concentrations of
nonsynonymous mutations are evident.
(PDF)
Figure S13 Amino acid alignment of the HCV Env
coding region of acute subject 10016. The H77 sequence
is shown at the top. Nonrandom concentrations of nonsynon-
ymous mutations are evident.
(PDF)
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Figure S14 HCV diversity analysis in subject 10020
suggests acute-to-acute transmission. Highlighter plot and
neighbor-joining tree of 59 quarter 1 genome sequences. Visualization
of 10 potential T/F viral sequences distinguished by unique shared
mutations is indicated by lower case (blue) letters. Model estimates of
T/F virus lineages using maximum (red) and average (green) cut-offs
reveals 5 and 3 potential T/F virus lineages, respectively, based on
increasingly stringent model assumptions (see text).
(PDF)
Figure S15 HCV diversity analysis in subject 10003
suggests acute-to-acute transmission. Highlighter plot and
neighbor-joining tree of 59 half genome sequences. Visualization of
37 potential T/F viral sequences distinguished by unique shared
mutations is indicated by lower case (blue) letters. Model estimates
of T/F virus lineages using maximum (red) and average (green)
cut-offs reveals 15 and 8 potential T/F virus lineages, respectively,
based on increasingly stringent model assumptions (see text).
(PDF)
Figure S16 HCV diversity in acute subject 9055. 59 half
genomesequences are color coded in green, blue and black in
chronological order to reflect sampling time points in Figure 1 and
are represented in a ML tree and Highlighter plot. Sequences show
evidence of productive clinical infection by one T/F virus with
mutations accumulating at positions 3311 and 3346 at the last
sampling time point coincident with antibody seroconversion.
Bootstrap values represent 100 repetitions. The horizontal scale
bar indicates genetic distance.
(PDF)
Figure S17 Nonsynonymous and synonymous mutations
in HCV sequences from acute subject 9055. A Highlighter plot
(panel A) of 59 half genomesequences is color coded to denote
nonynonymous (red) and synonymous (green) mutations. The boxed
area reveals a temporal expansion of sequences with concentrated
amino acid subtitutions in NS3. In panel B, amino acid selection is
evident in a previously identified CTL epitope highlighted in red. The
top-most sequence represents the genotype 3a consensus.
(PDF)
Figure S18 Polymerase template switching. Template
switching by the RNA polymerase between minus sense and plus
sense strands of double-stranded HCV RNA resulted in short
stretches of perfect inverted repeat sequences. Five examples are
illustrated in panels A–E. Proposed mechanisms for template
switching are illustrated.
(PDF)
Table S1 Diversity analysis of HCV 59 half genome
sequences from 14 chronically infected subjects.
(DOC)
Table S2 Estimates of numbers of T/F viruses in acute
HCV infection using empirical and model based meth-
ods.
(DOC)
Table S3 Estimation of numbers of T/F viruses by time
point using model-based methods with different cut-
offs.
(DOC)
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